COMMUNIQUÉS West-GlobeNewswire

Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
08/03/2019
Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; [...]
Achillion to Present at the Barclays Global Healthcare Conference
08/03/2019
BLUE BELL, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by [...]
Trading in GN Store Nord shares by board members, executives and associated persons
08/03/2019
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
08/03/2019
Orphazyme A/S Company announcement No. 09/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 8, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), [...]
Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer
08/03/2019
Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development [...]
EssilorLuxottica: 2018 pro forma results - Solid growth, sound profitability and cash flow - A robust foundation for EssilorLuxottica
08/03/2019
2018 pro forma 1 results Solid growth, sound profitability and cash flow A robust foundation for EssilorLuxottica PDF Version of the news release Pro forma 1 revenue: +3.2% at constant exchange rates 3 Pro forma 1 [...]
EssilorLuxottica: Résultats pro forma 2018 - Croissance, rentabilité et trésorerie solides - Un socle robuste pour EssilorLuxottica
08/03/2019
Résultats pro forma 1 2018 Croissance, rentabilité et trésorerie solides Un socle robuste pour EssilorLuxottica Version pdf du communiqué Chiffre d'affaires pro forma 1 : + 3,2 % à taux de change constants 3 Résultat [...]
Darolutamide submitted for European marketing authorization
08/03/2019
Orion Corporation Press Release Communications 8 March 2019 at 8:30 a.m. EET Darolutamide submitted for European marketing authorization Orion Corporation and Bayer today announced that a marketing authorization [...]
ERYTECH to Present at Cowen & Company 39th Annual Healthcare Conference Meeting
08/03/2019
LYON, France and CAMBRIDGE, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating [...]
ERYTECH annonce sa participation à la 39ème conférence Santé de Cowen
08/03/2019
LYON, France, 08 mars 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext : ERYP ; Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les [...]
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
08/03/2019
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) FDA to undertake priority review of Dupixent ® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps PARIS and [...]
Sanofi : La FDA accorde un examen prioritaire à la demande d'approbation de Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne sévère, inadéquatement contrôlée, de l'adulte
08/03/2019
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NASDAQ : SNY) La FDA accorde un examen prioritaire à la demande d'approbation de Dupixent ® (dupilumab) dans le traitement de la polypose nasosinusienne sévère, [...]
Addex Trading Update in Accordance with Art. 53 of the SIX Listing Rules (Ad hoc publicity)
08/03/2019
Geneva, Switzerland, 8 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today an unaudited operating loss of CHF1.6 milion [...]
QIAGEN and Tecan announce collaboration to streamline preanalytical processing of QuantiFERON-TB Gold Plus
08/03/2019
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection Männedorf, Switzerland, and [...]
Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin
07/03/2019
RICHMOND HILL, Ontario, March 07, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results
07/03/2019
Issues 2019 Revenue Guidance MEDFORD, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported [...]
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
07/03/2019
SYDNEY, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
07/03/2019
FREMONT, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March [...]
Cue Biopharma to Host Business Update Call and Webcast
07/03/2019
CAMBRIDGE, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the [...]

Pages